Evidence map›Paper›PMID 39391764›Full record

ArticleMolecular therapy. Nucleic acids2024

The beauty of symmetry: siRNA phosphorodithioate modifications reduce stereocomplexity, ease analysis, and can improve

Sophie Schöllkopf, Stefan Rathjen, Micaela Graglia, Nina Was, Eliot Morrison, Adrien Weingärtner, Lucas Bethge, Judith Hauptmann, Marie Wikström Lindholm

Abstract read
In one paragraph

Article in Molecular therapy. Nucleic acids, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Synthesis ofThe Journal of organic chemistry · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sophie SchöllkopfSilence Therapeutics GmbH, Robert-Rössle-Street 10, 13125 Berlin, Germany.
Stefan RathjenSilence Therapeutics GmbH, Robert-Rössle-Street 10, 13125 Berlin, Germany.
Micaela GragliaSilence Therapeutics GmbH, Robert-Rössle-Street 10, 13125 Berlin, Germany.
Nina WasSilence Therapeutics GmbH, Robert-Rössle-Street 10, 13125 Berlin, Germany.
Eliot MorrisonSilence Therapeutics GmbH, Robert-Rössle-Street 10, 13125 Berlin, Germany.
Adrien WeingärtnerSilence Therapeutics GmbH, Robert-Rössle-Street 10, 13125 Berlin, Germany.
Lucas BethgeSilence Therapeutics GmbH, Robert-Rössle-Street 10, 13125 Berlin, Germany.
Judith HauptmannSilence Therapeutics GmbH, Robert-Rössle-Street 10, 13125 Berlin, Germany.
Marie Wikström LindholmSilence Therapeutics GmbH, Robert-Rössle-Street 10, 13125 Berlin, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Phosphorothioates (PSs) can be essential in stabilizing therapeutic oligonucleotides against enzymatic degradation. However, unless synthesis is performed with stereodefined amidites, each PS introduces a chemically undefined stereocenter, resulting in 2

Indexed as

GalNAcMT: Oligonucleotides: Therapies and ApplicationsphosphorodithioatephosphorothioatesiRNA conjugatestabilizationstereodefinedstereoisomerstereopure

Identifiers

PMID39391764
PMCPMC11465064

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.